Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (21-30 of 187) with videos related to

Pageof 19
Sort By:
Expert Opinion on Investigational Drugs|November 30, 2004
The therapeutic potential of agents targeting the type I insulin-like growth factor receptorHua Zhang, Douglas Yee
Molecular Endocrinology (Baltimore, Md.)|September 15, 2015
Minireview: Were the IGF Signaling Inhibitors All Bad?Heather Beckwith, Douglas Yee
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 10, 2014
Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapyHeather Beckwith, Douglas Yee
Cancer Research|April 2, 2014
IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-Yuzhe Yang, Douglas Yee
Journal of Mammary Gland Biology and Neoplasia|October 12, 2012
Targeting insulin and insulin-like growth factor signaling in breast cancerYuzhe Yang, Douglas Yee
Cancer Metastasis Reviews|July 30, 2003
The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevanceJennifer M Gross, Douglas Yee
Women'S Health (London, England)|December 17, 2008
Progesterone and breast cancerCarol A Lange, Douglas Yee
Journal of Mammary Gland Biology and Neoplasia|November 26, 2008
The IGF system in mammary development and breast cancer. PrefaceDouglas Yee, Teresa L Wood
Endocrine-Related Cancer|May 27, 2011
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancerCarol A Lange, Douglas Yee
Breast Cancer Research : BCR|May 12, 2012
Estrogen-related receptor alpha: an orphan finds a familyAleksandra M Ochnik, Douglas Yee
Pageof 19

Showing results (21-30 of 187) with videos related to

Sort By:
Pageof 19
Expert Opinion on Investigational Drugs|November 30, 2004
The therapeutic potential of agents targeting the type I insulin-like growth factor receptorHua Zhang, Douglas Yee
Molecular Endocrinology (Baltimore, Md.)|September 15, 2015
Minireview: Were the IGF Signaling Inhibitors All Bad?Heather Beckwith, Douglas Yee
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 10, 2014
Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapyHeather Beckwith, Douglas Yee
Cancer Research|April 2, 2014
IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-Yuzhe Yang, Douglas Yee
Journal of Mammary Gland Biology and Neoplasia|October 12, 2012
Targeting insulin and insulin-like growth factor signaling in breast cancerYuzhe Yang, Douglas Yee
Cancer Metastasis Reviews|July 30, 2003
The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevanceJennifer M Gross, Douglas Yee
Women'S Health (London, England)|December 17, 2008
Progesterone and breast cancerCarol A Lange, Douglas Yee
Journal of Mammary Gland Biology and Neoplasia|November 26, 2008
The IGF system in mammary development and breast cancer. PrefaceDouglas Yee, Teresa L Wood
Endocrine-Related Cancer|May 27, 2011
Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancerCarol A Lange, Douglas Yee
Breast Cancer Research : BCR|May 12, 2012
Estrogen-related receptor alpha: an orphan finds a familyAleksandra M Ochnik, Douglas Yee
Pageof 19